Aquaporin-1: a novel promoter of tumor angiogenesis

Carmen Clapp1, Gonzalo Martínez de la Escalera

  • 1Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus UNAM-Juriquilla, Querétaro, Qro, México 76230. clapp@servidor.unam.mx

Insights

Aquaporin-1 protein is essential for tumor blood vessel formation. Deleting this water channel protein significantly hinders tumor growth and neovascularization.

Area of Science:

  • Oncology
  • Vascular Biology
  • Molecular Biology

Background:

  • Solid tumor growth relies heavily on angiogenesis, the formation of new blood vessels.
  • Understanding the molecular mechanisms of tumor angiogenesis is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the role of aquaporin-1 in tumor angiogenesis.
  • To elucidate the impact of aquaporin-1 deletion on tumor neovascularization and growth.

Main Methods:

  • Utilizing genetic deletion models to remove aquaporin-1.
  • Analyzing tumor angiogenesis and growth dynamics in the absence of aquaporin-1.

Main Results:

  • Deletion of aquaporin-1 significantly impairs tumor angiogenesis.
  • Reduced neovascularization directly correlates with inhibited tumor growth.

Conclusions:

  • Aquaporin-1 plays a critical role in supporting tumor angiogenesis.
  • Targeting aquaporin-1 may represent a novel therapeutic strategy to inhibit solid tumor growth.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...